GLP-1 RAs linked to better breast-cancer outcomes in obesity or T2D (JAMA Network Open 2026)
Provenance: peer-reviewed journal via a reputable oncology network
Retrospective cohort led by Virginia Commonwealth University Massey Comprehensive Cancer Center, published in JAMA Network Open (May 11, 2026); reported by Oncology Central. Observational — association only.
Key findings
- EHR analysis of >840,000 breast-cancer patients (2006–2023).
- In obesity: GLP-1 RA use → lower all-cause mortality (HR 0.35) and better recurrence-free survival (HR 0.44) over 10 years.
- In type-2 diabetes: vs insulin/metformin → all-cause mortality HR 0.09 and recurrence-free survival HR 0.33.
Why it matters for this base
- Reinforces the GLP-1 cancer-protective signal (alongside SOURCE-asco2026-glp1-cancer-progression) and the metabolism→cancer-outcome link — relevant to the Longevity protocol.
Caveats
- Observational; the authors stress randomized trials are needed before claiming GLP-1 RAs directly improve cancer outcomes.
Corroborating sources
- The ASCO Post; Pharmacy Times; HealthDay; Endocrinology Advisor (May 2026).